Genome-Wide Analysis Using Exon Arrays Demonstrates an Important Role for Expression of Extra-Cellular Matrix, Fibrotic Control and Tissue Remodelling Genes in Dupuytren's Disease

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Forrester, Helen B ^a   Temple Smith, Peter ^a,b,c   Ham, Seungmin ^a,b   de Kretser, David ^a,b   Southwick, Graeme ^a,c   Sprung, Carl N ^a  

^a MONASH UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c Melbourne Institute of Plastic Surgery   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FIBROBLAST GROWTH FACTOR 9; FIBROMODULIN; FOLLISTATIN; INTERSTITIAL COLLAGENASE; KERATIN; KINESIN; MATRIX METALLOPROTEINASE 16; RHO KINASE; STAT1 PROTEIN; STROMELYSIN; WNT PROTEIN; MATRIX METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

ACTA1 GENE; ACTA2 GENE; ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CELL ADHESION GENE; CELL CYCLE GENE; CLINICAL ARTICLE; COLLAGEN GENE; CONTROLLED STUDY; DISEASE CONTROL; DNA MICROARRAY; DUPUYTREN CONTRACTURE; EXTRACELLULAR MATRIX; FEMALE; FIBROBLAST GROWTH FACTOR 11 GENE; FIBROBLAST GROWTH FACTOR 9 GENE; FIBROMODULIN GENE; FIBROSIS; FOLLISTATIN GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE IDENTIFICATION; GENE PRODUCT; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE GENE; KERATIN GENE; KINESIN GENE; LOXL3 GENE; MALE; MATRIX METALLOPROTEINASE 1 GENE; MATRIX METALLOPROTEINASE 16 GENE; MATRIX METALLOPROTEINASE 3 GENE; MOLECULAR PATHOLOGY; NUCLEOTIDE SEQUENCE; RHO ASSOCIATED GENE; SERPINH1 GENE; STAT1 PROTEIN GENE; TISSUE REPAIR; UNINDEXED SEQUENCE; WNT PROTEIN GENE; CASE CONTROL STUDY; CLUSTER ANALYSIS; EXOME; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; MULTIGENE FAMILY; REPRODUCIBILITY;

ADULT; AGED; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; COLLAGEN; DUPUYTREN CONTRACTURE; EXOME; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; FIBROSIS; FOLLISTATIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MOLECULAR SEQUENCE ANNOTATION; MULTIGENE FAMILY; REPRODUCIBILITY OF RESULTS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84874878783     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059056     Document Type: Article

References (70)

1. Niessen FB, Spauwen PH, Schalkwijk J, Kon M, (1999) On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg 104: 1435-1458.
2. Bowley E, O'Gorman DB, Gan BS, (2007) Beta-catenin signaling in fibroproliferative disease. J Surg Res 138: 141-150.
3. Rayan GM, (2007) Dupuytren disease: Anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am 89: 189-198.
4. Desai SS, Hentz VR, (2010) Collagenase clostridium histolyticum for Dupuytren's contracture. Expert Opin Biol Ther 10: 1395-1404.
5. Rayan GM, (1999) Clinical presentation and types of Dupuytren's disease. Hand Clin15: 87-96, vii.
6. Thurston AJ, (2003) Dupuytren's disease. J Bone Joint Surg Br 85: 469-477.
7. Yi IS, Johnson G, Moneim MS, (1999) Etiology of Dupuytren's disease. Hand Clin15: 43-51, vi.
8. Murrell GA, Hueston JT, (1990) Aetiology of Dupuytren's contracture. Aust N Z J Surg 60: 247-252.
9. Slattery D, (2010) Review: Dupuytren's disease in Asia and the migration theory of Dupuytren's disease. ANZ J Surg 80: 495-499.
10. Burge P, (1999) Genetics of Dupuytren's disease. Hand Clin15: 63-71.
11. Gudmundsson KG, Arngrimsson R, Sigfusson N, Bjornsson A, Jonsson T, (2000) Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study. J Clin Epidemiol 53: 291-296.
12. Ling RS, (1963) The genetic factor in Dupuytren's disease. J Bone Joint Surg Br 45: 709-718.
13. Ross DC, (1999) Epidemiology of Dupuytren's disease. Hand Clin15: 53-62, vi.
14. Bocanegra TS, King P, Vasey FB, Germain BF, Espinoza LR, (1981) Dupuytren's contracture: a genetically predisposed disorder? J Rheumatol 8: 1026-1027.
15. Anthony SG, Lozano-Calderon SA, Simmons BP, Jupiter JB, (2008) Gender ratio of Dupuytren's disease in the modern U.S. population. Hand (N Y) 3: 87-90.
16. Al-Qattan MM, (2006) Factors in the pathogenesis of Dupuytren's contracture. J Hand Surg Am 31: 1527-1534.
17. Townley WA, Baker R, Sheppard N, Grobbelaar AO, (2006) Dupuytren's contracture unfolded. BMJ 332: 397-400.
18. Hueston JT (1963) Dupuytren's contnracture: Williams & Wilkins Co.
19. Hindocha S, McGrouther DA, Bayat A, (2009) Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (N Y) 4: 256-269.
20. van Rijssen AL, Gerbrandy FS, Ter Linden H, Klip H, Werker PM, (2006) A comparison of the direct outcomes of percutaneous needle fasciotomy and limited fasciectomy for Dupuytren's disease: a 6-week follow-up study. J Hand Surg Am 31: 717-725.
21. van Rijssen AL, Werker PM, (2006) Percutaneous needle fasciotomy in dupuytren's disease. J Hand Surg Br 31: 498-501.
22. Bainbridge C, Gerber RA, Szczypa PP, Smith T, Kushner H,et al. (2012) Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture. J Plast Surg Hand Surg.
23. Coleman S, Gilpin D, Tursi J, Kaufman G, Jones N, et al. (2012) Multiple concurrent collagenase clostridium histolyticum injections to dupuytren's cords: an exploratory study. BMC Musculoskelet Disord 13: 61.
24. Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, et al. (2009) Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 361: 968-979.
25. Desai SS, Hentz VR, (2011) The treatment of Dupuytren disease. J Hand Surg Am 36: 936-942.
26. Augoff K, Kula J, Gosk J, Rutowski R, (2005) Epidermal growth factor in Dupuytren's disease. Plast Reconstr Surg 115: 128-133.
27. Bisson MA, McGrouther DA, Mudera V, Grobbelaar AO, (2003) The different characteristics of Dupuytren's disease fibroblasts derived from either nodule or cord: expression of alpha-smooth muscle actin and the response to stimulation by TGF-beta1. J Hand Surg Br 28: 351-356.
28. Shih B, Watson S, Bayat A, (2012) Whole genome and global expression profiling of Dupuytren's disease: systematic review of current findings and future perspectives. Ann Rheum Dis.
29. Qian A, Meals RA, Rajfer J, Gonzalez-Cadavid NF, (2004) Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 64: 399-404.
30. Forsman M, Paakkonen V, Tjaderhane L, Vuoristo J, Kallioinen L, et al. (2008) The expression of myoglobin and ROR2 protein in Dupuytren's disease. J Surg Res 146: 271-275.
31. Rehman S, Salway F, Stanley JK, Ollier WE, Day P, et al. (2008) Molecular phenotypic descriptors of Dupuytren's disease defined using informatics analysis of the transcriptome. J Hand Surg Am 33: 359-372.
32. Zhang AY, Fong KD, Pham H, Nacamuli RP, Longaker MT, et al. (2008) Gene expression analysis of Dupuytren's disease: the role of TGF-beta2. J Hand Surg Eur Vol 33: 783-790.
33. Johnston P, Chojnowski AJ, Davidson RK, Riley GP, Donell ST, et al. (2007) A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease. J Hand Surg Am 32: 343-351.
34. Johnston P, Larson D, Clark IM, Chojnowski AJ, (2008) Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease. J Hand Surg Am 33: 1160-1167.
35. Lee LC, Zhang AY, Chong AK, Pham H, Longaker MT, et al. (2006) Expression of a novel gene, MafB, in Dupuytren's disease. J Hand Surg Am 31: 211-218.
36. Shih B, Wijeratne D, Armstrong DJ, Lindau T, Day P, et al. (2009) Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. J Hand Surg Am 34: 124-136.
37. Satish L, LaFramboise WA, O'Gorman DB, Johnson S, Janto B, et al. (2008) Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's Contracture. BMC Med Genomics 1: 10.
38. Branton MH, Kopp JB, (1999) TGF-beta and fibrosis. Microbes Infect 1: 1349-1365.
39. Krause C, Kloen P, Ten Dijke P, (2011) Elevated transforming growth factor beta and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Fibrogenesis Tissue Repair 4: 14.
40. Sgonc R, Wick G, (2008) Pro- and anti-fibrotic effects of TGF-beta in scleroderma. Rheumatology (Oxford) 47Suppl 5: v5-7.
41. Dolmans GH, Werker PM, Hennies HC, Furniss D, Festen EA, et al. (2011) Wnt signaling and Dupuytren's disease. N Engl J Med 365: 307-317.
42. O'Gorman DB, Wu Y, Seney S, Zhu RD, Gan BS, (2006) Wnt expression is not correlated with beta-catenin dysregulation in Dupuytren's Disease. J Negat Results Biomed 5: 13.
43. Satish L, Gallo PH, Baratz ME, Johnson S, Kathju S, (2011) Reversal of TGF-beta1 stimulation of alpha-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's-derived fibroblasts. BMC Musculoskelet Disord 12: 113.
44. Gilpin D, Coleman S, Hall S, Houston A, Karrasch J,et al. (2010) Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am 35: 2027-2038 e2021.
45. Sprung CN, Chao M, Leong T, McKay MJ, (2005) Chromosomal radiosensitivity in two cell lineages derived from clinically radiosensitive cancer patients. Clin Cancer Res 11: 6352-6358.
46. Bengtsson H, Simpson K, Bullard J, Hansen K (2006) Aroma. affymetris: A generic framework in R for analyaing small to very large Affymetrix data sets in bounded memory.: University of California, Berkeley. 745 745.
47. Pan D, Watson HK, Swigart C, Thomson JG, Honig SC, et al. (2003) Microarray gene analysis and expression profiles of Dupuytren's contracture. Ann Plast Surg 50: 618-622.
48. Chammas M, Bousquet P, Renard E, Poirier JL, Jaffiol C, et al. (1995) Dupuytren's disease, carpal tunnel syndrome, trigger finger, and diabetes mellitus. J Hand Surg Am 20: 109-114.
49. Ratkaj I, Bujak M, Jurisic D, Baus Loncar M, Bendelja K, et al. (2012) Microarray Analysis of Dupuytren's Disease Cells: The Profibrogenic Role of the TGF-beta Inducible p38 MAPK Pathway. Cell Physiol Biochem 30: 927-942.
50. Rehman S, Xu Y, Dunn WB, Day PJ, Westerhoff HV, et al. (2012) Dupuytren's disease metabolite analyses reveals alterations following initial short-term fibroblast culturing. Mol Biosyst.
51. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, et al. (2002) Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A 99: 12877-12882.
52. Bazin S, Le Lous M, Duance VC, Sims TJ, Bailey AJ, et al. (1980) Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. Eur J Clin Invest 10: 9-16.
53. Murrell GA, Francis MJ, Bromley L, (1987) Free radicals and Dupuytren's contracture. Br Med J (Clin Res Ed) 295: 1373-1375.
54. Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJ, (1987) Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J 248: 265-268.
55. Rozen WM, Edirisinghe Y, Crock J, (2012) Late Complications of Clinical Clostridium Histolyticum Collagenase Use in Dupuytren's Disease. PLoS ONE 7: e43406.
56. Pegorier S, Campbell GA, Kay AB, Lloyd CM, (2010) Bone morphogenetic protein (BMP)-4 and BMP-7 regulate differentially transforming growth factor (TGF)-beta1 in normal human lung fibroblasts (NHLF). Respir Res 11: 85.
57. Nikolova G, Jabs N, Konstantinova I, Domogatskaya A, Tryggvason K, et al. (2006) The vascular basement membrane: a niche for insulin gene expression and Beta cell proliferation. Dev Cell 10: 397-405.
58. Noble J, Heathcote JG, Cohen H, (1984) Diabetes mellitus in the aetiology of Dupuytren's disease. J Bone Joint Surg Br 66: 322-325.
59. Grootaert C, Van de Wiele T, Verstraete W, Bracke M, Vanhoecke B, (2012) Angiopoietin-like protein 4: health effects, modulating agents and structure-function relationships. Expert Rev Proteomics 9: 181-199.
60. Akiyama SK, (1996) Integrins in cell adhesion and signaling. Hum Cell 9: 181-186.
61. Patella S, Phillips DJ, Tchongue J, de Kretser DM, Sievert W, (2006) Follistatin attenuates early liver fibrosis: effects on hepatic stellate cell activation and hepatocyte apoptosis. Am J Physiol Gastrointest Liver Physiol 290: G137-144.
62. Antsiferova M, Huber M, Meyer M, Piwko-Czuchra A, Ramadan T, et al. (2011) Activin enhances skin tumourigenesis and malignant progression by inducing a pro-tumourigenic immune cell response. Nat Commun 2: 576.
63. Tsuchida K, Nakatani M, Hitachi K, Uezumi A, Sunada Y, et al. (2009) Activin signaling as an emerging target for therapeutic interventions. Cell Commun Signal 7: 15.
64. Aoki F, Kurabayashi M, Hasegawa Y, Kojima I, (2005) Attenuation of bleomycin-induced pulmonary fibrosis by follistatin. Am J Respir Crit Care Med 172: 713-720.
65. Ludlow H, Phillips DJ, Myers M, McLachlan RI, de Kretser DM, et al. (2009) A new 'total' activin B enzyme-linked immunosorbent assay (ELISA): development and validation for human samples. Clin Endocrinol (Oxf) 71: 867-873.
66. Badalamente MA, Hurst LC, Grandia SK, Sampson SP, (1992) Platelet-derived growth factor in Dupuytren's disease. J Hand Surg Am 17: 317-323.
67. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R, (1990) TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63: 515-524.
68. Lawler J, McHenry K, Duquette M, Derick L, (1995) Characterization of human thrombospondin-4. J Biol Chem 270: 2809-2814.
69. Sprung CN, Li J, Hovan D, McKay MJ, Forrester HB, (2011) Alternative transcript initiation and splicing as a response to DNA damage. PLoS ONE 6: e25758.
70. Forrester HB, Li J, Hovan D, Ivashkevich AN, Sprung CN, (2012) DNA repair genes: alternative transcription and gene expression at the exon level in response to the DNA damaging agent, ionizing radiation. PLoS ONE 7: e53358.